New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines

Research doesn ’t endonce a medicine is first approved by the U.S. Food and Drug Administration (FDA). Researchers often spend years after an initial approval exploring and obtaining approval of new indications for medicines to treat other patient populations desperate for new treatment options. Patients with cancer or rare diseases often depend on this post-approval research.
Source: The Catalyst - Category: Pharmaceuticals Tags: Research and Development Rare Diseases Cancer Government Price Setting Source Type: news